Cover Image
市場調查報告書

Eiger BioPharmaceuticals, Inc.:產品平台分析

Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251663
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Eiger BioPharmaceuticals, Inc.:產品平台分析 Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月12日 內容資訊: 英文 27 Pages
簡介

Eiger BioPharmaceuticals, Inc.是總公司設於美國的生物製藥企業,正在研究開發肝炎治療藥物的抗病毒藥物。該公司正在開發候補物質有EBP921,EBP994的肝炎三角洲型病毒(HDV)的複製化及異戊烯酶抑製劑等。

本報告提供Eiger BioPharmaceuticals, Inc.治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Eiger BioPharmaceuticals, Inc.的基本資料

  • Eiger BioPharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Eiger BioPharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Eiger BioPharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Eiger BioPharmaceuticals, Inc.:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Eiger BioPharmaceuticals, Inc.:藥物簡介

  • EBP-921
  • lonafarnib
  • EBP-1597

Eiger BioPharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Eiger BioPharmaceuticals, Inc.:開發暫停中的計劃

Eiger BioPharmaceuticals, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07501CDB

Summary

Global Markets Direct's, 'Eiger BioPharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Eiger BioPharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Eiger BioPharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Eiger BioPharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Eiger BioPharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Eiger BioPharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Eiger BioPharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Eiger BioPharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Eiger BioPharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Eiger BioPharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Eiger BioPharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Eiger BioPharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Eiger BioPharmaceuticals, Inc. Snapshot
    • Eiger BioPharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Eiger BioPharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Eiger BioPharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products Glance
    • Eiger BioPharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
  • Eiger BioPharmaceuticals, Inc. - Drug Profiles
    • EBP-921
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EBP-922
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lonafarnib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tipifarnib
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Eiger BioPharmaceuticals, Inc. - Pipeline Analysis
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Target
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Route of Administration
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Eiger BioPharmaceuticals, Inc. - Recent Pipeline Updates
  • Eiger BioPharmaceuticals, Inc. - Dormant Projects
  • Eiger BioPharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Eiger BioPharmaceuticals, Inc., Key Information
  • Eiger BioPharmaceuticals, Inc., Key Facts
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Eiger BioPharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Eiger BioPharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Eiger BioPharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Eiger BioPharmaceuticals, Inc. - Phase II, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Target, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Eiger BioPharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Eiger BioPharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Eiger BioPharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Eiger BioPharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top